DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone

AsiaNet 51149

OSAKA, Oct. 25, 2012 /PRN=KYODO JBN/ --

    Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan)

and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka,

Japan) today announced that the European Medicines Agency (EMA) has confirmed

the acceptance for review of the Marketing Authorization Application (MAA) for

an atypical antipsychotic medication lurasidone hydrochloride for the treatment

of schizophrenia. The MAA was filed by Takeda Global Research & Development

Centre (Europe).

    Lurasidone, orally administrated once daily, is an atypical antipsychotic

medication discovered and developed by DSP with a unique chemical structure as

compared to other existing antipsychotic medicines. Takeda entered into a

license agreement with DSP stipulating the joint development and grant of an

exclusive commercialization right of the product to Takeda in 26 member states

of the European Union (excluding the United Kingdom), and Switzerland, Norway,

Turkey and Russia in March 2011.

    The MAA submission is based on the data from more than 50 clinical trials

involving more than 3,800 lurasidone-treated subjects. In phase 3 clinical

trials, in which the efficacy and safety of lurasidone in the treatment of

patients with schizophrenia were evaluated, lurasidone demonstrated

significantly greater improvement versus placebo in the primary efficacy

endpoint [Positive and Negative Syndrome Scale (PANSS)* total score]. The most

commonly observed adverse reactions in patients treated with lurasidone were

somnolence, akathisia, nausea and parkinsonism. Clinical trials also

demonstrated that lurasidone was well-tolerated with minimal impact on weight

or metabolic parameters.

    "Lurasidone is the DSP Group's core product for overseas expansion, and I

am very pleased that we have achieved the important milestone of submitting an

MAA in Europe." said Masayo Tada, President and Chief Executive Officer of DSP.

"Through the cooperation between our two companies, we are aiming for the

swiftest approval in order to provide this drug to more patients as soon as

possible."

    "We are very pleased with the submission of lurasidone in the E.U.," said

Yasuchika Hasegawa, president & CEO of Takeda. "We believe the submission will

lead to the enhancement of our central nervous system franchise, one of our

core therapeutic areas. Once approved, we believe we can contribute to the

treatment of patients with schizophrenia."

    * A medical scale used for mainly measuring symptom severity of patients

with schizophrenia. It consists of 30 items---7 items of positive scale, 7

items of negative scale and 16 items of general psychopathology scale. Each

item is rated from 1 (absent) to 7 (extreme).

    About lurasidone

    Lurasidone is an atypical antipsychotic, developed originally by DSP with

an affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors

where it has antagonist effects.  In addition, lurasidone is a partial agonist

at the serotonin 5-HT1A receptor and has no appreciable affinity for histamine

or muscarinic receptors.

    Lurasidone (brand name LATUDA(R)) was approved for the treatment of

schizophrenia by the United States Food and Drug Administration on 28 October

2010 and by Health Canada on 13 June 2012.  LATUDA was launched in the United

States for the treatment of schizophrenia in adults on February 4, 2011 (US

time) and in Canada on September 17, 2011 (Canada Time) through DSP's

subsidiary Sunovion Pharmaceuticals Inc.  

    In the U.S. and Canada, the recommended starting dose for LATUDA is

40mg/day taken with food (at least 350 calories) with no initial dose titration

required.  The maximum recommended dose is 160 mg/day.  The efficacy of

lurasidone for the treatment of schizophrenia was established in five,

short-term (6-week), placebo-controlled clinical studies in adult patients who

met DSM-IV criteria for schizophrenia. In these studies, lurasidone

demonstrated significantly greater improvement versus placebo on the primary

efficacy measures [the Positive and Negative Syndrome Scale (PANSS) total score

and the Brief Psychiatric Rating Scale-derived from PANSS (BPRSd)] at study

endpoint. Clinical trials contributed to the understanding of the tolerability

and safety profile of lurasidone. The most commonly observed adverse reactions

(greater than or equal to 5% and at least twice that for placebo) in patients

treated with lurasidone in short-term clinical studies were somnolence,

akathisia, nausea and parkinsonism. Efficacy and safety of lurasidone were also

demonstrated in long-term studies.

    About Dainippon Sumitomo Pharma Co., Ltd.

    Dainippon Sumitomo Pharma Co., Ltd., defines its corporate mission as "to

broadly contribute to society through value creation based on innovative

research and development activities for the betterment of healthcare and fuller

lives for people worldwide". By pouring all our efforts into the research and

development of new drugs, we aim to provide innovative and effective

pharmaceutical solutions to people not only in Japan but also around the world

in order to realize our corporate mission. Additional information about DSP is

available through its corporate website, http://www.ds-pharma.com.

    About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its

main focus on pharmaceuticals. As the largest pharmaceutical company in Japan

and one of the global leaders of the industry, Takeda is committed to strive

towards better health for patients worldwide through leading innovation in

medicine. Additional information about Takeda is available through its

corporate website, http://www.takeda.com.

    SOURCE: Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma

Co., Ltd.